ArticleTranslational cancer research2025
Integrative analysis of polo-like kinase family identifies a prognostic signature and validates PLK2 as a therapeutic target in glioma.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glioma is a common malignant tumor of the central nervous system, characterized by aggressive behavior and poor prognosis. The polo-like kinase (PLK) gene family plays a crucial role in cell cycle regulation, but its expression and functional roles in glioma remain incompletely understood. This study aimed to systematically characterize the expression landscape and prognostic significance of the PLK gene family in glioma and to experimentally evaluate the therapeutic potential of PLK2 inhibition. Methods: We performed a comprehensive analysis using RNA transcriptome sequencing data and clinical information from 1,018 glioma patients. The expression patterns and prognostic significance of PLK family genes were evaluated in relation to tumor grade and molecular markers. A prognostic model based on PLK gene expression was developed and validated. Gene Ontology (GO) enrichment analysis was conducted to explore PLK2-associated biological functions. Functional experiments, including Cell Counting Kit-8 (CCK-8) viability assay, colony formation assay, and transwell migration assay, were performed to assess the effect of the PLK2-specific inhibitor ON1231320 on glioblastoma (GBM) cell lines. Results: Conclusions: Our study highlights the prognostic value of the PLK gene family in glioma and identifies PLK2 as a promising therapeutic target. The PLK2 inhibitor ON1231320 shows potential as an anti-GBM agent and warrants further investigation in preclinical and clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.